GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Fushilai Pharmaceutical Co Ltd (SZSE:301258) » Definitions » EV-to-Revenue

Suzhou Fushilai Pharmaceutical Co (SZSE:301258) EV-to-Revenue : 2.68 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Suzhou Fushilai Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Suzhou Fushilai Pharmaceutical Co's enterprise value is ¥1,148.5 Mil. Suzhou Fushilai Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥429.1 Mil. Therefore, Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue for today is 2.68.

The historical rank and industry rank for Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SZSE:301258' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.52   Med: 3.75   Max: 6.47
Current: 2.78

During the past 11 years, the highest EV-to-Revenue of Suzhou Fushilai Pharmaceutical Co was 6.47. The lowest was 1.52. And the median was 3.75.

SZSE:301258's EV-to-Revenue is ranked better than
73.6% of 1038 companies
in the Biotechnology industry
Industry Median: 7.985 vs SZSE:301258: 2.78

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Suzhou Fushilai Pharmaceutical Co's stock price is ¥27.75. Suzhou Fushilai Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥4.67. Therefore, Suzhou Fushilai Pharmaceutical Co's PS Ratio for today is 5.95.


Suzhou Fushilai Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Fushilai Pharmaceutical Co EV-to-Revenue Chart

Suzhou Fushilai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.84 3.15

Suzhou Fushilai Pharmaceutical Co Quarterly Data
Jun18 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 3.66 4.01 3.15 2.19

Competitive Comparison of Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue

For the Biotechnology subindustry, Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue falls into.



Suzhou Fushilai Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1148.451/429.089
=2.68

Suzhou Fushilai Pharmaceutical Co's current Enterprise Value is ¥1,148.5 Mil.
Suzhou Fushilai Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥429.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Fushilai Pharmaceutical Co  (SZSE:301258) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Suzhou Fushilai Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=27.75/4.667
=5.95

Suzhou Fushilai Pharmaceutical Co's share price for today is ¥27.75.
Suzhou Fushilai Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.67.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Fushilai Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Suzhou Fushilai Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Fushilai Pharmaceutical Co (SZSE:301258) Business Description

Traded in Other Exchanges
N/A
Address
No. 16, Haiwang Road, New Material Industrial Park, Jiangsu Province, Changshu, CHN, 215500
Suzhou Fushilai Pharmaceutical Co Ltd is engaged in the Research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products. The products are mainly used in the fields of medicine, dietary supplements and cosmetics, and have significant effects in anti-oxidation, anti-aging, and blood sugar improvement.
Executives
Qian Yi Supervisors

Suzhou Fushilai Pharmaceutical Co (SZSE:301258) Headlines

No Headlines